-+ 0.00%
-+ 0.00%
-+ 0.00%

GeoVax FY25 net loss narrows 14% to $21,464,771

PUBT·04/15/2026 19:58:28
Listen to the news
GeoVax FY25 net loss narrows 14% to $21,464,771
  • GeoVax posted fiscal 2025 net loss of USD 21.5 million, narrowing from USD 25 million.
  • Revenue slid 37.1% to USD 2.5 million.
  • Operating loss tightened to USD 21.6 million from USD 25.1 million.
  • Research and development expense fell 24% to USD 18.1 million due to discontinued costs tied to BARDA’s termination of ATI-RRPV contract.
  • GeoVax said existing cash and cash equivalents of USD 3.1 million should fund operations into mid-second quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-012377), on April 15, 2026, and is solely responsible for the information contained therein.